NewsBenzingainTest Q3 Adj. EPS $0.18 Beats $0.12 Estimate, Sales $35.069M Beat $34.800M Estimate inTest Q3 Adj. EPS $0.18 Beats $0.12 Estimate, Sales $35.069M Beat $34.800M Estimate Benzinga 2026.11.06 11:16 (GMT+0) Open on Benzinga Other news Piper Sandler Maintains Overweight on ICU Medical, Raises Price Target to $200 Keybanc Maintains Overweight on Five9, Raises Price Target to $34 Piper Sandler Maintains Neutral on Collegium Pharmaceutical, Lowers Price Target to $28 Keybanc Maintains Overweight on FIGS, Raises Price Target to $27 Reported Earlier, Kazakhstan Says Oil Exports To Germany Won't Resume By End Of 2026 Piper Sandler Maintains Neutral on Becton Dickinson, Raises Price Target to $200
